Danielle Bucco

Articles

Finn Highlights Practice-Changing Studies in Liver Cancer

September 16th 2017

The 11th International Liver Cancer Association Annual Conference, taking place September 15 to 17 in Seoul, South Korea, is showcasing multidisciplinary findings across the field of hepatocellular carcinoma.

Novel Agent HXR9 Attacks New Target in AML

August 31st 2017

Richard Morgan, MD, discusses recent research involving therapy with HXR9 for patients with AML.

BRCA1/2 Mutation Genetic Status Linked With Platinum Resistance in Breast and Ovarian Cancers

August 31st 2017

Katherine Nathanson, MD, discusses how the genetics of BRCA1/2-associated tumors impacts tumor development in breast and ovarian cancer and response to treatment.

Researcher Highlights Emerging Role of RET Inhibitors in NSCLC

August 29th 2017

Christine M. Lovly, MD, PhD, discusses the importance of identifying and targeting RET in non-small cell lung cancer.

Optimizing Immunotherapy Remains a Challenge in NSCLC

August 29th 2017

David R. Gandara, MD, discusses the latest immunotherapy developments in lung cancer and the next steps toward optimizing the benefit of these agents.

Lead Investigator Discusses Atezolizumab/Bevacizumab in mRCC

August 25th 2017

Michael B. Atkins, MD, discusses the latest IMmotion150 findings and additional developments with immunotherapy in mRCC.

Expert Discusses Impact of Muscle-Invasive Bladder Cancer Guidelines

August 24th 2017

The guidelines provide evidence-based recommendations on staging, neoadjuvant and adjuvant chemotherapy, radical cystectomy, urinary diversion, perioperative surgical management, and pelvic lymphadenectomy.

Expert Discusses Next Steps for Durvalumab in Bladder Cancer

August 23rd 2017

Peter Black, MD, discusses the latest on durvalumab and other ongoing developments in the field of bladder cancer.

Esteva Explains State of Genomic Testing in Breast Cancer

August 23rd 2017

Francisco J. Esteva, MD, PhD, discusses the clinical implications of genomic testing for patients with metastatic breast cancer.

Andtbacka Discusses Long-Term Data and Next Steps With T-VEC in Melanoma

August 22nd 2017

Robert Andtbacka, MD, discusses the long-term results for T-VEC in melanoma and the remaining challenges with the oncolytic immunotherapy.

Expert Discusses Robotic Surgery in RCC

August 22nd 2017

Ketan K. Badani, MD, discusses the benefits of robotic surgery in RCC and use of the technique among urologists.

High Cadmium Levels Linked to Increased Endometrial Cancer Risk

August 14th 2017

Jane McElroy, PhD, discusses the association between higher cadmium levels and an increased risk of endometrial cancer.

Expert Discusses Promise of Mirvetuximab Soravtansine in Ovarian Cancer

August 14th 2017

Kathleen Moore, MD, discusses the potential of mirvetuximab soravtansine in patients with epithelial ovarian cancer.

Lead Researcher Discusses Latest Pertuzumab Data in HER2+ Breast Cancer

August 12th 2017

Gunter von Minckwitz, MD, PhD, discusses the APHINITY results and their implication for the use of pertuzumab in patients with HER2-positive breast cancer.

Loeb Discusses Genomic Testing and Accurate Prostate Cancer Staging

August 11th 2017

Stacy Loeb, MD, discusses the promise and challenges with genomic testing in prostate cancer.

Expert Discusses QOL at 2 Years Following Prostate Cancer Treatment

August 10th 2017

Andrew Stephenson, MD, discusses the impact of various approaches—radiation, surgery, and active surveillance—on patients’ quality of life 2 years following treatment.

Expert Discusses CMB305 Immunotherapy Regimen in Sarcoma

August 7th 2017

Neeta Somaiah, MD, discusses the efficacy of CMB305 in patients with synovial sarcoma or myxoid/round cell liposarcoma.

Experts Explain Impact of LATITUDE Abiraterone Data in Prostate Cancer

August 3rd 2017

Jorge Garcia, MD, and Kim Chi, MD, share their insights on the LATITUDE trial in prostate cancer.

Pembrolizumab Plus Epacadostat Active in RCC

August 2nd 2017

Primo N. Lara Jr, MD, discusses the KEYNOTE-037 pembrolizumab/epacadostat findings in patients with advanced RCC, and how the combination could change treatment in this population.

Axicabtagene Ciloleucel Emerges as Potential Standard for Some NHL Patients

July 25th 2017

Sattva S. Neelapu, MD, discusses the latest results for axicabtagene ciloleucel (KTE-C19) for transplant-ineligible patients with relapsed/refractory non-Hodgkin lymphoma and the CAR T-cell therapy’s potential to be a new standard of care.